These findings suggest that CTHRC1 may serve as a diagnostic biomarker for identifying patients who experience severe COVID-19 symptoms and are at risk of developing post-COVID-19 pulmonary fibrosis. This evidence concerns the gene CTHRC1 and COVID-19.